The latest price target for Eton Pharmaceuticals (NASDAQ:ETON) was reported by HC Wainwright & Co. on May 15, 2026. The analyst firm set a price target for $57.00 expecting ETON to rise to within 12 months (a possible 63.70% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Eton Pharmaceuticals (NASDAQ:ETON) was provided by HC Wainwright & Co., and Eton Pharmaceuticals maintained their buy rating.

There is no last upgrade for Eton Pharmaceuticals

There is no last downgrade for Eton Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eton Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eton Pharmaceuticals was filed on May 15, 2026 so you should expect the next rating to be made available sometime around May 15, 2027.

While ratings are subjective and will change, the latest Eton Pharmaceuticals (ETON) rating was a maintained with a price target of $52.00 to $57.00. The current price Eton Pharmaceuticals (ETON) is trading at is $34.82, which is out of the analyst’s predicted range.